Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

ABSTRACT:

Objectives

Pharmacological treatment of Alzheimer's disease focuses on correcting the cholinergic deficiency in the central nervous system with cholinesterase inhibitors. Three cholinesterase inhibitors are currently recommended: donepezil, rivastigmine, and galantamine. This review assessed the scientific evidence for the recommendation of these agents.

Data sources

The terms "donepezil", "rivastigmine", and "galantamine", limited by "randomized-controlled-trials" were searched in Medline (1989-November 2004), Embase (1989-November 2004), and the Cochrane Database of Systematic Reviews without restriction for language.

Study selection

All published, double blind, randomised controlled trials examining efficacy on the basis of clinical outcomes, in which treatment wit

SUBMITTER: Kaduszkiewicz H 

PROVIDER: S-EPMC1183129 | biostudies-literature | 2005 Aug

REPOSITORIES: biostudies-literature